Gilead Sciences Inc.
Foster City, CA Doing business as Gilead
- UEI
- FPJMGUK1BYH8
- CAGE
- 0SFJ8
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Gilead Sciences Inc.
FPJMGUK1BYH8
- Asegua Therapeutics LLC JNQMSQ4JQ6A9
- Bristol Myers Squibb & Gilead Sciences, LLC RE9JJU8VA989
- CV Therapeutics Incorporated TLAWUCWBE1B5
- Immunomedics, Inc. S4NHH3294XM6
-
Gilead Sciences Inc.
FPJMGUK1BYH8
- SAM.gov registration date
- Physical address
- 333 Lakeside Dr, Foster City, CA 94404, USA
- Website
- gilead.com
- Founded
- 1987
- Employees
- 10K-50K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Lenacapavir (sunlenca) | Veterans Integrated Service Network 21 | $14,894 | |
| Sunlenca 300MG tab,PKT,5 | Veterans Integrated Service Network 20 | $3,103 | |
| Sunlenca 300MG tab,PKT,4 | Veterans Integrated Service Network 20 | $2,482 | |
| Sulenca INJ | Veterans Integrated Service Network 5 | $14,938 | |
| Lenacapavir | Veterans Integrated Service Network 20 | $47,797 |
About Gilead Sciences Inc.
Gilead Sciences Inc., headquartered in Foster City, California, is a prominent biopharmaceutical company registered to receive federal contract awards since May 31, 2001. The company specializes in developing and commercializing innovative pharmaceutical products, with a primary focus on advanced medical treatments across various therapeutic areas, including antiviral medications, cancer immunotherapies, and drugs for complex medical conditions. Gilead provides critical pharmaceutical products to federal healthcare programs, particularly the Department of Veterans Affairs (VA), through its General Services Administration (GSA) Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB).
Through its federal contract awards, Gilead has consistently supplied specialized pharmaceutical products to the VA, with a significant emphasis on COVID-19 treatments, oncology medications, and HIV therapies. The company's contract awards primarily involve delivery orders for specific medications such as Veklury (remdesivir) for COVID-19 treatment, Yescarta and Tecartus CAR T-cell therapies for cancer treatment, and Lenacapavir for HIV treatment. These contracts have been awarded across multiple Veterans Integrated Service Networks (VISN) and have consistently been awarded without small business set-aside designations, indicating Gilead's status as a large prime contractor. The contract values have ranged from approximately $3,000 to over $300,000, demonstrating the company's ability to provide both small and large pharmaceutical supply orders to federal healthcare systems.
Gilead holds a significant Blanket Purchase Agreement (BPA) with the VA National Acquisition Center, valued at $29,160,000.00 and running through October 31, 2025. This single-award BPA covers the procurement of specialized pharmaceutical products including Letairis, Yescarta, Tecartus, and more recently, Livdelzi. The BPA is structured under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule, which enables VA medical facilities nationwide to efficiently order these critical medications as needed. This IDV complements Gilead's existing multiple-award Federal Supply Schedule contract, valued at $33 million, which allows various federal agencies to purchase from Gilead's comprehensive pharmaceutical portfolio. These contract vehicles underscore Gilead's strategic importance as a supplier of advanced medical treatments to federal healthcare programs, particularly for complex and life-threatening conditions affecting veterans and other federal healthcare beneficiaries.
Contract vehicles
Quick answers
What is Gilead Sciences Inc.'s UEI?
Gilead Sciences Inc.'s Unique Entity ID (UEI) in SAM.gov is FPJMGUK1BYH8.
What is Gilead Sciences Inc.'s CAGE code?
Gilead Sciences Inc.'s CAGE code is 0SFJ8.
What is Gilead Sciences Inc.'s primary NAICS code?
Gilead Sciences Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Gilead Sciences Inc. located?
Gilead Sciences Inc.'s physical address in SAM.gov is 333 Lakeside Dr, Foster City, CA 94404, USA.
Is Gilead Sciences Inc. registered in SAM.gov?
Yes. Gilead Sciences Inc.'s SAM.gov registration is active through February 24, 2027.
Which contract vehicles does Gilead Sciences Inc. hold?
Gilead Sciences Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Gilead Sciences Inc.'s most recent federal award?
Gilead Sciences Inc.'s most recent federal contract award is Lenacapavir (sunlenca) (36C26125N0499), from Veterans Integrated Service Network 21, on May 14, 2025.
On GovTribe
See Gilead Sciences Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors